Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Authors
Discussion
Loading...
Member takes
Implication
Randomized double-blind trial reports baseline profiles for finerenone in non-diabetic chronic kidney disease, suggesting new therapeutic options beyond diabetes.
Key Points
- The FIND-CKD trial investigates whether finerenone slows chronic kidney disease progression in patients without diabetes receiving renin angiotensin system inhibitors.
- Baseline screening randomized 1584 participants who exhibited a mean estimated glomerular filtration rate of 46.7 ml/min/1.73 m2 across diverse international clinical sites.
- Randomized, double-blind, placebo-controlled trial tests mineralocorticoid receptor antagonist efficacy on long-term renal outcomes, with final treatment results pending.
Cite This Study
Heerspink et al. (2024) studied this question.